Ett större företag med bra information är amerikanska Celgene.
De bedriver forskning inom bland annat Immunonkologi. Från deras sida plockar jag relevant info för oss noviser att lära ifrån. Och en film som gör det enklare att förstå. För, vi pratar forskning på den allra högsta nivån.
Även vi i Sverige har forskare på denna nivå. Tänk exempelvis GlycoImaging.
Immuno-Oncology
Celgene is exploring immuno-oncology therapies targeting multiple cell types associated with anti-tumor responses. In collaboration with key partners, Celgene is investigating B-cell functions relevant to tumor immunology, stimulating T-cell immunity against hematologic and solid tumors, modulating innate immunity and NK cell function to enhance tumor cell killing, reducing immunosuppressive effects of suppressor cells, and modulating the metabolic state of immune cells and the tumor microenvironment to stimulate antitumor response in cancer patients. Although tumor cells use multiple mechanisms to evade immune response development of these immunotherapeutic approaches may assist in the elimination of tumor cells by the immune system.Researching the Modulation of the Immune System to Attack Cancer Cells
Celgene is researching immune-based therapies targeting multiple cell types involved in antitumor immune response, such as T cells, B cells, NK cells, and macrophages.
From viruses and bacteria to the bodies’ own sick and dying cells, immune cells search out and destroy the trouble-makers.
But cancer cells can be tricky; they have ways of hiding from the immune system.
The ability of tumor cells to evade the immune response is a key reason why cancers can be so difficult to treat.
That’s why researchers are creating tools to help patients’ immune cells better detect and then kill tumor cells.
One method that’s recently become available for childhood leukemia is to engineer a patient’s own T cells – a type of white blood cell – to recognize proteins found on the surface of the cancer cells.
This type of therapy is called chimeric antigen receptor (CAR) T cell therapy.
With CAR T cell technology, doctors remove some T cells from a patient and genetically modify them with a homing beacon for proteins made by tumors.
The newly armed T cells are then multiplied into the billions and infused back into the patient to hunt down the cancer.
The type of CAR engineered for a patient depends on his or her cancer. For example, the special receptor might target a protein called CD19, which sits on the surface of many leukemias and lymphomas, including diffuse large B cell lymphoma.
Or the CAR might be designed to draw T cells to a protein called B-cell maturation antigen, which is found on tumor cells in up to 70 percent of patients with multiple myeloma.
Researchers are currently investigating ways to enhance this technology by finely tuning the ratio of different kinds of T cells given back to the patient. The idea is to give patients just the right combination of the cells that carry out the killing (called CD8 T cells) and the cells (CD4 T cells) that are thought to help make the assassins more mobile and recruit additional immune cells.[i]
While CAR T cell therapies use markers on the outside of cancer cells to fight them, another immune strategy in development looks inside. In this case, the patient’s immune cells are given an engineered T cell receptor (TCR) that helps it recognize pieces of proteins from within cancer cells.
When these protein bits find their way to the surface of the tumor cell, the engineered TCR helps the T cell latch on tightly to the cancer cell.
Whether from within or without, cancer cells make proteins that reveal them as unwanted guests in the body.
Harnessing the power of the immune system to better detect these flags may one day offer new hope to patients who currently have few options.
-------------------------------------------------------------------------------------------------------------------------
Det kan för övrigt nämnas att Celgene är aktuellt av annan anledning än sin forskning.
Bjässen Bristol-Myers Squibb är för närvarande i slutet av förhandlingar att köpa upp Celgene.
Man har lagt ett bud på 74 Miljarder Dollar för att komma över företaget.
Ett förvärv som insatta ser som logiskt i dessa tider av konsolidering.
Bloggen använder hellre ord som : Bamseföretag köper upp mindre företag för att de har en portfölj av intressant forskning som Bamse själv inte vill hosta upp flis för att bedriva i egen regi.
Hellre pröjsar Bamse, som i detta fallet ca 700 Miljarder Skr, och gör det förmodligen i förvissningen att de kommer tjäna bra på den affären.
Intressant i sammanhanget är att insatta analytiker ser detta förvärv som en risk för B-M Squibb.
Risken är att en än större Bamse kommer köpa upp B-M Squibb efter de inkorporerat Celgene.
Det pratas i så fall om Johnson&Johnson,Pfizer och Amgen, att någon av dessa Bamse-Bamse-Bjässar plockar fram den stora plånboken och glufsar i sig lill-bamsen B-M Squibb.
Intressant utveckling att se fram mot mao.
Nåväl,vad berör detta PHI då undrar vän av ordning?
Tja, inte annat än att det visar på hur hiskeligt stora pengar det kan handla om när det sker affärer inom läkemedelsindustrin. Vill Bamse X köpa upp lilla företaget Y, av skäl mer än de mest uppenbara, finns resurser som heter duga.
Mvh the99
Revealing Cancer Cells to the Immune System
New technologies may help immune cells identify cancer cells using tags on their inside or out
The immune system is the body’s main level of defense against a hostile world.From viruses and bacteria to the bodies’ own sick and dying cells, immune cells search out and destroy the trouble-makers.
But cancer cells can be tricky; they have ways of hiding from the immune system.
The ability of tumor cells to evade the immune response is a key reason why cancers can be so difficult to treat.
That’s why researchers are creating tools to help patients’ immune cells better detect and then kill tumor cells.
One method that’s recently become available for childhood leukemia is to engineer a patient’s own T cells – a type of white blood cell – to recognize proteins found on the surface of the cancer cells.
This type of therapy is called chimeric antigen receptor (CAR) T cell therapy.
With CAR T cell technology, doctors remove some T cells from a patient and genetically modify them with a homing beacon for proteins made by tumors.
The newly armed T cells are then multiplied into the billions and infused back into the patient to hunt down the cancer.
The type of CAR engineered for a patient depends on his or her cancer. For example, the special receptor might target a protein called CD19, which sits on the surface of many leukemias and lymphomas, including diffuse large B cell lymphoma.
Or the CAR might be designed to draw T cells to a protein called B-cell maturation antigen, which is found on tumor cells in up to 70 percent of patients with multiple myeloma.
Researchers are currently investigating ways to enhance this technology by finely tuning the ratio of different kinds of T cells given back to the patient. The idea is to give patients just the right combination of the cells that carry out the killing (called CD8 T cells) and the cells (CD4 T cells) that are thought to help make the assassins more mobile and recruit additional immune cells.[i]
While CAR T cell therapies use markers on the outside of cancer cells to fight them, another immune strategy in development looks inside. In this case, the patient’s immune cells are given an engineered T cell receptor (TCR) that helps it recognize pieces of proteins from within cancer cells.
When these protein bits find their way to the surface of the tumor cell, the engineered TCR helps the T cell latch on tightly to the cancer cell.
Whether from within or without, cancer cells make proteins that reveal them as unwanted guests in the body.
Harnessing the power of the immune system to better detect these flags may one day offer new hope to patients who currently have few options.
-------------------------------------------------------------------------------------------------------------------------
Det kan för övrigt nämnas att Celgene är aktuellt av annan anledning än sin forskning.
Bjässen Bristol-Myers Squibb är för närvarande i slutet av förhandlingar att köpa upp Celgene.
Man har lagt ett bud på 74 Miljarder Dollar för att komma över företaget.
Ett förvärv som insatta ser som logiskt i dessa tider av konsolidering.
Bloggen använder hellre ord som : Bamseföretag köper upp mindre företag för att de har en portfölj av intressant forskning som Bamse själv inte vill hosta upp flis för att bedriva i egen regi.
Hellre pröjsar Bamse, som i detta fallet ca 700 Miljarder Skr, och gör det förmodligen i förvissningen att de kommer tjäna bra på den affären.
Intressant i sammanhanget är att insatta analytiker ser detta förvärv som en risk för B-M Squibb.
Risken är att en än större Bamse kommer köpa upp B-M Squibb efter de inkorporerat Celgene.
Det pratas i så fall om Johnson&Johnson,Pfizer och Amgen, att någon av dessa Bamse-Bamse-Bjässar plockar fram den stora plånboken och glufsar i sig lill-bamsen B-M Squibb.
Intressant utveckling att se fram mot mao.
Nåväl,vad berör detta PHI då undrar vän av ordning?
Tja, inte annat än att det visar på hur hiskeligt stora pengar det kan handla om när det sker affärer inom läkemedelsindustrin. Vill Bamse X köpa upp lilla företaget Y, av skäl mer än de mest uppenbara, finns resurser som heter duga.
Mvh the99
Inga kommentarer:
Skicka en kommentar